[FETV=김창수 기자] South Korean scientists have announced that the world’s first discovery of a substance that degrades corona 19 replication is underway in Korea and Italy, giving new hope to the world.
Kim Hong-ryul, ceo of Heimbio, which is developing the next-generation anticancer drug candidate, The Ambassador Cancer Drug Starvanip, said, “For the first time in the world, we have jointly researched corona 19 therapeutic candidates without side effects in collaboration with the research team at Yonsei University Medical School,” announced on April 4.
Kim explained, “Based on the inorganic polyphosphate study, we have jointly identified important clues to the possibility of developing corona 19 virus drugs without side effects for the first time in the world.”
The discovery of the replication function of corona 19 virus host using this human polymer is the result of a joint study conducted by Heimbio Kim Hong-ryul with a research team at Yonsei University Medical School.
Polyphosphate (Polyphosphate) is a material that has already been certified by the FDA as an additive in food or medicine, and has already been proven to be safe.
Kim said, “Recently, domestic corona virus infection (COVID-19) confirmor sample was provided with a confirmor sample, and observed in Yonsei University how the human polymer of various chain lengths acts on the corona virus at various different concentrations in the corona virus, and found for the first time that corona virus replication is suppressed in the host cell at a significant level in certain chain lengths and other concentrations.”
Immediately after the discovery, the results were sent to Dr. Massimo Zolo of the Institute of Biotechnology CEINGE in Naples, Italy, and is currently comparing the virus collected from samples of corona virus infectious diseases (COVID-19) in Italy confirmed in Italy using pharyngeal cells (oropharyngeal cell) to the same polymerized samples used in Korean experiments.
Kim said, “We compared the gene sequence sequencing of confirmor samples collected from a number of European countries, including Korea and Italy, and shared the fact that various parts of the sequence sequence were mutated. Based on this, in-depth research on mutations in virus replication capacity is currently underway rapidly in cooperation with overseas researchers. In addition, experiments that inhibit the ability of human polymers to replicate actual infections using confirmer samples are currently being conducted in italian laboratories.”
The “human polymer”, which was discovered as a candidate for treatment of Corona 19, has been a steady study since the 1960s by Dr. Arthur Conberg, who won the Nobel Prize in Medicine in 1959. The study was started in 1997 by a German research team, which found that multiple chain-length human polymers have the ability to inhibit infection in another virus, HIV-H1.
Human polymer is a substance that is found in almost all organisms, such as bacteria, fungi, plants, mammals as a polymer that forms a linear connection to at least 1000 phosphates (phosphate, PO43-) in at least three.
In particular, human polymer is an important precursor material that is the origin of life is an energy metabolites of all cells, ATP sources, energy sources, storage of phosphoric acid, binding to metal ions, regulators for stress and survival, inorganic compounds that have a variety of functions such as generating control factors using genes and related genes to produce foreign substances are a possible material for a variety of new drugs.
Kim, korea’s first human polymer research expert, said, “Human polymer research began in 1993 while attending Stanford Medical School in the United States. It was a study that started while conducting postdoctoral training under the guidance of Nobel Prize winner Dr. Arthur Conberg.
While studying molecular genetics at Carlton University in Canada, Kim studied plasmid DNA replication in dysentery. Dna replication and polymer field studies of postdoctoral studies at Stanford Medical School in the United States have found an infarction-regulation phenomenon on enzymes that create foreign substances in soil bacteria that induce asthma in particular to give fatal results to pulmonary fibroblasts. He is also the creator of the Biochemistry Department of Kyunghee University.
Kim said, “We have completed a patent application for a pharmaceutical composition for the prevention and treatment of corona virus infectious diseases. The patent was 100% agreed upon by co-inventors and the transfer key to Heimbio, and will be published in detail soon through international journals. The development of anti-cancer drugs for spray products and incurable molecular carcinoma using human polymers is also underway. We plan to continue research in the future from various perspectives that require the development of coronavirus drugs and vaccines.”
On 20 July, professor Remy Scharrell of the University of Marseille in France recently published a pre-publication platform (bioRxiv) after heating the Corona 19 virus from 60° to 140°C in a 60°c image, and “some strains have shocked the world by announcing that the virus is still replicated even in heated for an hour.”
The severity of the corona virus replication is being done at more than 60 degrees Celsius, as the new issue emerged, the discovery of substances that can inhibit the replication of the corona virus is a welcome thing worldwide.
Heimbio is developing the metabolic anti-cancer drug “Starvanip” (NYH817100), a next-generation anti-cancer drug candidate that starves cancer cells. Currently, Yonsei University Severance Hospital oncology is undergoing clinical phase 1 for a variety of cancer patients who have failed standard treatment in Korea.